Contact Information: For More Information, Contact: James E. Fickenscher Chief Financial Officer Auxilium Pharmaceuticals, Inc. (484) 321-5900 Gregory Gin Lazar Partners, Ltd. (212) 867-1762
Auxilium Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
| Source: Auxilium Pharmaceuticals, Inc.
MALVERN, PA--(Marketwire - September 20, 2007) - Auxilium Pharmaceuticals, Inc. (NASDAQ : AUXL )
today announced that Mr. Armando Anido, Chief Executive Officer and
President, and Mr. Jim Fickenscher, Chief Financial Officer, will
participate in the 2007 UBS Global Life Sciences Conference to be held
September 24 through September 27, 2007 at the Grand Hyatt Hotel in New
York City. Mr. Anido is scheduled to present an overview of the Company
and its product pipeline at 8:30 AM Eastern Time on Thursday, September 27,
2007.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for 30 days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets
Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism
through its approximately 190-person sales and marketing team. Auxilium
has four projects in clinical development. XIAFLEX™ (clostridial
collagenase for injection), formerly referred to as AA4500, is in phase
III of development for the treatment of Dupuytren's contracture and is in
phase II of development for the treatment of Peyronie's disease and Frozen
Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film
product candidate for the treatment of overactive bladder (AA4010) is in
phase I of development. The Company is currently seeking a partner to
further develop this product candidate. Auxilium has two pain products
using its transmucosal film delivery system in pre-clinical development.
Auxilium has rights to six additional pain products and products for
hormone replacement and urologic disease using its transmucosal film
delivery system. Auxilium also has options to all indications using
XIAFLEX for non-topical formulations. For additional information, visit
http://www.auxilium.com.
SAFE HARBOR STATEMENT
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the 2007 UBS Global Life
Sciences Conference, and products in development for the treatment of
Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome,
pain, hormone replacement and urologic disease. All statements other than
statements of historical facts contained in this release, including but not
limited to, statements regarding future expectations, plans and prospects
for the Company, statements regarding forward-looking financial information
and other statements containing the words "believe," "may," "could,"
"will," "estimate," "continue," "anticipate," "intend," "should," "plan,"
"expect," and similar expressions, as they relate to the Company,
constitute forward-looking statements. Actual results may differ materially
from those reflected in these forward-looking statements due to various
factors, including general financial, economic, regulatory and political
conditions affecting the biotechnology and pharmaceutical industries and
those discussed in the Company's Annual Report on Form 10-K for the year
ended December 31, 2006 and in the Company's Annual Report on Form 10-Q for
the quarter ended June 30, 2007 under the heading "Risk Factors," which is
on file with the Securities and Exchange Commission (the "SEC") and may be
accessed electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of the Company's home page on the Internet
at http://www.auxilium.com under the heading "Investor Relations -- SEC
Filings." There may be additional risks that the Company does not presently
know or that the Company currently believes are immaterial which could also
cause actual results to differ from those contained in the forward-looking
statements. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.